SGLT-2 Therapy Center

Detection of euglycemic ketoacidosis could be a challenge for physicians since this condition can mask an underlying diabetic ketoacidosis.

2016 FDA warning conflicts with recent evidence showing no increased risk following use of treatment.

Benefits of SGLT2 inhibitors in patients treated with insulin.

First real-world study comparing SGLT2i therapies also showed patients taking INVOKANA 300 mg significantly less likely to discontinue treatment or switch to another diabetes medicine.

SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors compared in reducing mortality and cardiovascular events in patients with type 2.

Treatment method reduced the amount of liver fat more than standard treatment alone.

Surprise findings for treatment class and appropriate patient selection

Why and when to use this therapy to treat patients who have type 2 diabetes.

Subanalysis of CANVAS program shows slower progression of kidney disease, reduction in weight, reduction in A1c and even drop in blood pressure.

Most important mediator due to changes in markers of plasma volume.